Mroczkowska-Bękarciak Aleksandra, Wróbel Tomasz
Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland.
Oncotarget. 2025 Feb 5;16:44-50. doi: 10.18632/oncotarget.28686.
The treatment of blood cancers has been revolutionized by hematopoietic stem cell transplantation. Owing to this method, we are able to effectively treat most blood cancers. However, in some cases, one of the greatest problems is the risk of relapse. Most often, relapse of the disease manifests itself as cancer cells with the same characteristics as the primary cancer. Nevertheless, a very small percentage of patients develop other blood cancers from donor cells. Donor cell-derived hematologic neoplasms are extremely rare complications that arise after hematopoietic stem cell transplantation.
In this study we described a patient who underwent hematopoietic stem cell transplantation due to acute myeloid leukemia and subsequently developed triple-negative myeloproliferative neoplasms with mutations in the , and genes 9 years later. Over the next two years, the disease progressed and MDS/AML developed. Unfortunately, the patient died during induction therapy.
Donor cell-derived hematologic neoplasms are rare but significant complications after HSCT. Early diagnosis and intervention are crucial to improving patient prognosis. Further studies are needed to better understand the pathogenesis of this condition and develop more effective therapeutic strategies.
造血干细胞移植彻底改变了血液癌症的治疗方式。借助这种方法，我们能够有效治疗大多数血液癌症。然而，在某些情况下，最大的问题之一是复发风险。疾病复发最常见的表现是癌细胞具有与原发性癌症相同的特征。不过，极小比例的患者会从供体细胞发展出其他血液癌症。供体细胞衍生的血液肿瘤是造血干细胞移植后出现的极其罕见的并发症。
在本研究中，我们描述了一名因急性髓系白血病接受造血干细胞移植的患者，9年后随后发展出具有 、 和 基因 突变的三阴性骨髓增殖性肿瘤。在接下来的两年里，疾病进展并发展为骨髓增生异常综合征/急性髓系白血病。不幸的是，患者在诱导治疗期间死亡。
供体细胞衍生的血液肿瘤是造血干细胞移植后罕见但严重的并发症。早期诊断和干预对于改善患者预后至关重要。需要进一步研究以更好地了解这种疾病的发病机制并制定更有效的治疗策略。
